Aegros
Christina Chen is a highly experienced professional in process development and validation within the pharmaceutical industry. Currently serving as the Senior Director of Process Development at Aegros since April 2022, Christina has accumulated extensive expertise over the years, including a significant role as a C&Q Engineer at CAI from April 2012 to May 2022. Prior experience includes positions at Foster Wheeler Asia Pacific Private Limited as a Pharma Process Engineer, where key commissioning projects included purified water and pure steam systems, along with protocol generation for various utilities. Christina also held the position of Senior Validation Engineer at A-Bio Pharma Pte Ltd, leading validation initiatives for facility expansions and equipment operation. Earlier in the career, Christina was a Process Engineer at Oculex Asia Pharmaceuticals, focusing on technology transfer and equipment evaluation. Christina holds a Bachelor of Engineering in Bioprocess from UNSW.
This person is not in any teams
This person is not in any offices
Aegros
At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the patient first through innovation and we do this thanks to our Australian invented Haemafrac®, Aegros' unique electroseparation process. Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma. Aegros is currently undertaking the final preparations for the submission of a dossier for the registration of this hyperimmune against Covid-19 on the Australian Register of Therapeutic Goods (ARTG) Simultaneously, Aegros is finishing the upgrade of its existing hyperimmune facility at Macquarie Park NSW to be able to process 100,000l of plasma per year.